



Phillippo, D., Dias, S., Welton, N., Taske, N., Naidoo, B., & Ades, T. (2016). Sensitivity of treatment decisions to bias adjustment in network metaanalysis. Abstract from 16th Biennial European Conference of the Society for Medical Decision Making, London, United Kingdom.

License (if available): Unspecified

Link to publication record in Explore Bristol Research PDF-document

#### University of Bristol - Explore Bristol Research General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms.html



bristol.ac.uk

# Sensitivity of treatment decisions to bias adjustment in network meta-analysis

David M. Phillippo<sup>1</sup>, Sofia Dias<sup>1</sup>, Nicky J. Welton<sup>1</sup>, Nichole Taske<sup>2</sup>, Bhash Naidoo<sup>2</sup>, A. E. Ades<sup>1</sup>

<sup>1</sup>School of Social and Community Medicine, University of Bristol, UK <sup>2</sup>National Institute for Health and Care Excellence (NICE), London, UK

SMDM European Conference



#### Overview

- Background and motivation
  - Network Meta-Analysis (NMA)
  - Quality vs. influence
- Threshold method
- Examples



bristol.ac.uk

## Background – Network Meta-Analysis

- Combines evidence on multiple treatments from several studies
- Arranges treatments on a network structure joined by study evidence
- Provides consistent estimates of treatment effects
- Routinely used to inform clinical guideline recommendations, technology appraisals



Mean change in

bristol.ac.uk

#### **Motivation – Headaches Example**



.....

	Treatment	headache days per month (95% Crl)
1	Placebo	0
2	Telmisartan	-0.51 (-2.32, 1.27)
3	Amitriptyline	-1.14 (-2.45, 0.16)
4	Divalproex Sodium	0.13 (-0.99, 1.23)
5	Gabapentin	0.00 (-1.60, 1.58)
6	Topiramate	-1.04 (-1.52, -0.58)
7	Propranolol	-1.19 (-2.20, -0.20)
8	Propranolol/Nadolol	-0.60 (-1.65, 0.45)

#### (NICE, 2015)

#### SMDM European Conference



bristol.ac.uk

#### Motivation

#### How robust are the results to bias?

• Evidence quality is only half the story

#### Quality





#### The Threshold Method

### Derive bias adjustment thresholds:

How much can we change a data point before the treatment recommendation changes?





bristol.ac.uk

#### The Threshold Method

### Derive bias adjustment thresholds:

How much can we change a data point before the treatment recommendation changes?





bristol.ac.uk

#### The Threshold Method

# Once we have thresholds we can create a *decision invariant bias adjustment interval* for a data point





#### The Threshold Method

- Study level
  - Thresholds for each individual study estimate
- Contrast level
  - Thresholds for combined body of evidence on a contrast
  - Highly flexible due to an approximation step



#### Example: Headaches





bristol.ac.uk

#### Example: Headaches – contrast level

Contrast	Posterior Mean	95% Credible Interval	Invariant Interval with		h						
2 vs. 1	-0.51	(-2.32, 1.27)	2	(–1.19, NT)	_			(			
4 vs. 1	0.13	(-0.99, 1.23)	4	(-1.19, NT)	_						
5 vs. 1	-0.00	(-1.60, 1.58)	5	(-1.18, NT)	_		-				_
<sup>†</sup> 6 vs. 1	-1.04	(-1.51, -0.58)	3	(-1.20, -0.09)	8						
<sup>†</sup> 7 vs. 1	-1.19	(-2.20, -0.20)	_	(NT, -1.04)	3			0			
8 vs. 1	-0.60	(-1.64, 0.45)	8	(–1.19, NT)	_		_	0			
<sup>†</sup> 6 vs. 3	0.10	(-1.13, 1.32)	_	(NT, 0.15)	3				o		
<sup>†</sup> 7 vs. 6	-0.15	(-1.11, 0.82)	_	(NT, -0.07)	3						
						[					
						-3	-2	-1	0	1	2
0	Posterior Mean	— 95% Credible Ir	iterval	Invaria	nt Interv	/al	Chang	e in headac	he days per	month	

# Shows thresholds for changes to a body of evidence between two treatments

SMDM European Conference

#### Example: Headaches – study level

Study (Trt.)	Posterior Mean	95% Confidence Interval	Invariant Interval with $\widetilde{k}^{\star}$													
Dien09 (1)	-1.14	(-2.26, -0.02)	_	(NT, -0.47)	2								-0	_		
Dien09 (2)	-1.65	(-2.72, -0.58)	2	(-2.32, NT)	-						_	0				
Apos08 (1)	-2.80	(-3.50, -2.10)	_	(NT, -1.48)	4											
Apos08 (4)	-3.10	(-3.93, -2.27)	4	(-7.92, 6.08)	3					_	_0	_				
Apos08 (4)	-2.20	(-2.93, -1.47)	4	(–6.15, 3.50)	3							-0	-	i		-
Apos08 (4)	-2.80	(-3.43, -2.17)	4	(-6.16, 16.23)	3											
Bran04 (1)	-1.30	(-1.93, -0.67)	8	(-5.64, -0.43)	3			1.1					-0			
Bran04 (6)	-2.90	(-3.53, -2.27)	3	(-5.01, 6.96)	8						<u> </u>	_		1		
Bran04 (6)	-2.60	(-3.21, -1.99)	3	(-4.57, 9.43)	8											
Bran04 (6)	-1.70	(-2.29, -1.11)	3	(-3.85, NT)	_											
Lewi09 (1)	-2.60	(-3.68, -1.52)	8	(–12.65, –1.12)	3					-	C					
Lewi09 (6)	-4.90	(-5.93, -3.87)	3	(-8.24, 10.40)	8											
Lewi09 (6)	-3.60	(-4.57, -2.63)	3	(-8.22, 19.98)	8					C						
Lipt11 (1)	-5.30	(-5.84, -4.76)	8	(-11.50, -4.47)	3			_	<b>—</b> —							
Lipt11 (6)	-6.60	(-7.14, -6.06)	3	(-8.38, -1.58)	8		0									
Silb04 (1)	-1.30	(-1.89, -0.71)	8	(-4.90, -0.62)	3								<b></b>			
Silb04 (6)	-2.70	(-3.30, -2.10)	3	(-5.56, 9.63)	8											
Silb04 (6)	-2.70	(-3.23, -2.17)	3	(-4.31, 9.00)	8							_				
Silb04 (6)	-2.70	(-3.25, -2.15)	3	(-4.15, 8.36)	8									i i		
Winn05 (1)	-2.40	(-3.18, -1.62)	2	(-12.07, -1.26)	3							<b></b>				
Winn05 (6)	-3.10	(-3.67, -2.53)	3	(-4.49, 5.40)	8					-	_0					
<sup>†</sup> Dien04 (1)	-1.10	(-1.57, -0.63)	3	(-1.29, NT)	_								_ <b></b> O			
<sup>†</sup> Dien04 (6)	-1.30	(-1.79, -0.81)	3	(–1.44, NT)	_							_	<b>-</b> O			
<sup>†</sup> Dien04 (6)	-1.80	(-2.29, -1.31)	3	(–1.94, NT)	_							-0	_	- i		
<sup>†</sup> Dien04 (7)	-1.90	(-2.39, -1.41)	_	(NT, -1.85)	3								-			
Holr10 (1)	-3.30	(-3.60, -3.00)	_	(NT, -2.71)	8						-0					
Holr10 (8)	-3.90	(-4.25, -3.55)	8	(-4.49, NT)	-					-0				i		
Silb13 (5 vs. 1)	0.00	(-1.30, 1.30)	5	(–1.19, NT)	_								_	<b></b>		
<sup>†</sup> Dodi09 (3 vs. 6	) –0.10	(-0.90, 0.70)	3	(–0.15, NT)	_									-0	-	
																٦
						-8	-7	-6	-5	-4	-3	-2	-1	0	1	2

\_\_\_\_



bristol.ac.uk

#### **Example: Social Anxiety**



- 41 treatments, 100 studies
- Class effect model with 17 classes
- NMA fed into CEA to give decision on net benefit scale

(NCC-MH, 2013)

#### Example: Social Anxiety – contrast level (efficacy)

Contrast	Posterior Mean	95% Credible Interval	Invariant Interval with $\widetilde{k}^{\star}$					
41 vs. 31	-0.88	(-1.27, -0.49)	– (NT, –0.42) 36					
41 vs. 23	-0.41	(-0.80, -0.02)	– (NT, 0.06) 36					
36 vs. 1	-1.56	(-1.86, -1.27)	36 (–2.05, 13.61) 7					
36 vs. 16	-0.69	(-1.04, -0.35)	36 (-1.26, 4.91) 16					
36 vs. 24	-0.73	(-1.06, -0.40)	36 (-1.42, 5.61) 25					
41 vs. 2	-1.21	(-1.60, -0.83)	– (NT, –0.39) 36					
17 vs. 2	-0.47	(-0.68, -0.26)	17 (–1.33, 50.71) 12					
13 vs. 2	-0.45	(-0.65, -0.25)	13 (–1.33, 139.66) 4					
39 vs. 18	-0.36	(-0.91, 0.18)	39 (-1.31, 3.60) 36					
38 vs. 21	-0.22	(-0.70, 0.27)	38 (–1.16, 3.71) 36					
18 vs. 2	-0.53	(-0.65, -0.40)	39 (-1.48, 8.79) 36					
23 vs. 2	-0.81	(-1.05, -0.56)	23 (-2.69, 0.17) 36					
36 vs. 2	-1.09	(-1.41, -0.77)	36 (-2.11, 34.05) 18					
16 vs. 2	-0.40	(-0.65, -0.14)	36 (-1.43, 17.40) 12					
19 vs. 2	-0.49	(-0.67, -0.32)	19 (–1.55, 29.73) 23					
25 vs. 24	-0.05	(-0.49, 0.39)	25 (-1.16, 554.74) 39					
31 vs. 8	0.07	(-0.17, 0.32)	31 (-13.67, 1.22) 36					
34 vs. 1	-1.02	(-1.42, -0.63)	34 (-2.21, 101.29) 5					
31 vs. 1	-0.80	(-1.02, -0.58)	31 (-16.38, 0.40) 36					
32 vs. 30	-0.25	(-0.61, 0.12)	32 (-1.57, 5.66) 36					
11 vs. 2	-0.42	(-0.89, 0.04)	11 (–1.84, 856.05) 34					
9 vs. 2	-0.25	(-0.51, 0.01)	9 (-1.68, 46.63) 36					
40 vs. 35	-0.05	(-0.52, 0.43)	40 (–1.53, 3.12) 36					
30 vs. 24	-0.02	(-0.27, 0.22)	30 (-8.80, 1.46) 36					
15 vs. 2	-0.41	(-0.63, -0.19)	15 (–1.92, 49.40) 23					
22 vs. 2	-0.27	(-0.48, -0.06)	22 (–1.81, 5.92) 18					
8 vs. 1	-0.88	(-1.04, -0.71)	8 (-2.86, 0.68) 36					
8 vs. 6	-0.21	(-0.46, 0.04)	8 (-13.40, 1.36) 6					
37 vs. 30	-0.10	(-0.46, 0.25)	37 (-1.84, 7.10) 36					
8 vs. 7	-0.03	(-0.34, 0.28)	8 (-17.13, 1.72) 7					
31 vs. 23	0.47	(0.21, 0.74)	36 (-1.32, 2.58) 23					
21 vs. 2	-0.60	(-0.95, -0.25)	21 (-2.41, 10.57) 36					
12 vs. 2	-0.33	(-0.93, 0.28)	12 (-2.30, 59.55) 36					



Posterior Mean

Standardised Mean Difference

#### Example: Social Anxiety – contrast level (net benefit)

Contrast	Posterior Mean	95% Credible Interval	Invarian	t Interval wit	th k*	_						
8 vs. 5	-0.03	(-0.27, 0.20)	5 (-6	3.05, 1.54)	5					_		
8 vs. 1	-0.88	(-1.04, -0.71)	5 (–2	2.58, 5.66)	5			-0-				
13 vs. 2	-0.45	(-0.65, -0.25)	13 (–2	2.17, 1.64)	13				———			
18 vs. 2	-0.53	(-0.65, -0.40)	18 (–2	2.34, 1.90)	18				-0-			
8 vs. 7	-0.03	(-0.34, 0.28)	— `(l	NT, 1.80)	7							
30 vs. 5	-0.01	(-0.27, 0.25)	5 (-7	7.57, 1.96)	5				—			
5 vs. 1	-0.84	(-1.08, -0.60)	5 (–:	3.15, 7.99)	5			-0-				
8 vs. 6	-0.21	(-0.46, 0.04)	8 (–1	8.57, 2.19)	6				——————————————————————————————————————			
15 vs. 2	-0.41	(-0.63, -0.19)	15 (–:	3.31, 2.99)	15				<b>—</b> —			
19 vs. 2	-0.49	(-0.67, -0.32)	19 (–:	3.42, 2.86)	19				-0-			
7 vs. 5	-0.01	(-0.34, 0.33)	7 (–:	3.44, 4.55)	5					<b></b>		
17 vs. 2	-0.47	(-0.68, -0.26)	17 ( <u>–</u> 4	1.06, 3.34)	17				<b>—</b> —			
12 vs. 2	-0.33	(-0.93, 0.28)	12 (-4	1.27, 3.63)	12							
16 vs. 2	-0.40	(-0.65, -0.14)	16 (–	5.18, 5.19)	16				——————————————————————————————————————			
18 vs. 15	-0.12	(-0.35, 0.11)	15 (-	5.74, 4.67)	15					-		
28 vs. 26	-0.17	(-0.60, 0.25)	- (	NT, 4.72)	27							
30 vs. 1	-0.85	(-1.04, -0.67)	5 (-6	3.42, 9.85)	16			-0-	-			
35 vs. 26	-0.93	(-1.39, -0.47)	- (	NT, 4.70)	27			O				
30 vs. 16	0.01	(-0.27, 0.29)	16 (-6	3.60, 5.67)	16				<b></b> ¢	<u> </u>		
14 vs. 2	-0.36	(-0.76, 0.05)	14 (-7	7.20, 7.15)	14			-				
14 vs. 1	-0.83	(-1.27, -0.39)	14 (–8	3.51, 7.60)	14			O	<u> </u>			
33 vs. 29	-0.35	(-0.68, -0.03)	- (	NT, 7.90)	30				<b></b>			
36 vs. 16	-0.69	(-1.04, -0.35)	16 (-1	0.61, 7.78)	16				<b></b>			
6 vs. 1	-0.66	(-0.94, -0.39)	6 (-	9.17, NT)	_				<b>~</b>			
23 vs. 2	-0.81	(-1.05, -0.56)	24 (-9	.38, 11.46)	18							
33 vs. 28	-0.54	(-0.95, -0.13)	- (	NT, 8.79)	27				<b></b>			
31 vs. 23	0.47	(0.21, 0.74)	12 (–1	8.59, 9.80)	24					<b>—</b> 0—		
19 vs. 18	0.03	(-0.16, 0.23)	19 (–9	.48, 10.94)	19					<u> </u>		
22 vs. 2	-0.27	(-0.48, -0.06)	12 (–1	3.06, 9.81)	18				<b></b> _			
35 vs. 1	-1.19	(-1.48, -0.89)	27 (-1	1.79, 17.33)	18			<b>—</b> —				
31 vs. 2	-0.33	(-0.57, -0.10)	18 (-14	1.95, 10.60)	18				<b></b>			
30 vs. 14	-0.02	(-0.47, 0.41)	14 (-12	2.55, 11.38)	14				ċ			
33 vs. 30	-0.12	(-0.37, 0.13)	- (N	JT, 11.47)	5					_		
									—i			
						_3	_2	_1	0		1	2
						-0	-2		U U	/		2





## Conclusions

- Provides insight into the effects of bias adjustment on treatment decisions
- Application to combined data on contrasts is highly flexible
- More confidence in recommendations where thresholds are large
- Focusses attention on the quality of decisionsensitive trials and contrasts



bristol.ac.uk

# Acknowledgements

National Institute for Health and Care Excellence This work was supported by the Centre for Clinical Practice, NICE, with funding to the Clinical Guidelines Technical Support Unit, University of Bristol.



This work was undertaken with the support of the MRC ConDuCT-II Hub (MR/K025643/1), and the MRC grant MR/M005232/1.

Phillippo D M, Welton N J, Dias S, Didelez V, Ades A E. *Bias-Adjustment Thresholds for Bayesian Network Meta-Analysis*. Submitted.



.....

14<sup>th</sup> June 2016

## Additional slides





bristol.ac.uk

#### The Threshold Method

Thresholds are derived for a data point by:

1. Asking for each non-optimal treatment how much adjustment would make that treatment optimal

Difference to overturn

Influence of data point

2. Taking the smallest positive and negative adjustments as the positive and negative thresholds



#### Extensions: Multiple simultaneous adjustments



SMDM European Conference

bristol.ac.uk



#### **Extensions: Psychological treatment bias**



SMDM European Conference